Elicio Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Elicio Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Self-Funding Ratio: Over the last 3 years operating cash was negative while the company kept spending on investment (capex). Lower than 96% of Healthcare companies in United States.
- Steadiness Ratio: Sales grew in 0 of the last 3 years; profit grew in 1 of 3. Less steady than 86% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
-631.4×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 96% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 1/3Sales grew in 0 of the last 3 years; profit grew in 1 of 3.
Less steady than 86% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-36.5×Operating cash was negative last year, while some debt falls due within a year.
Lower than 67% of Healthcare companies in United States.
Cash Cushion Ratio
+8%Cash, after subtracting all debt, equals 8% of its market value (net cash).
Lower than 53% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (11)
Elicio Therapeutics, Inc. made a loss over the last year. Elicio Therapeutics, Inc. owes $0.75 for every $1 it owns. Elicio Therapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossElicio Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
6.62The share price is 6.62 times Elicio Therapeutics, Inc.'s book value per share, higher than 79% of Healthcare companies in United States.
Market cap
$53 MThe total market value of all of Elicio Therapeutics, Inc.'s shares at today's price (share price × number of shares), smaller than 73% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
$8 MWhat Elicio Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$0.29Net worth divided by the number of shares. The share price of $1.94 is 6.6 times this, which is the P/B above.
Return on equity (ROE)
-774.6%Elicio Therapeutics, Inc. lost 774.6% of its shareholders' money over the last year, lower than 96% of Healthcare companies in United States.
Owes vs Owns
0.75×Elicio Therapeutics, Inc. owes $0.75 for every $1 it owns (moderate), higher than 75% of Healthcare companies in United States.
Dividend yield
NoneElicio Therapeutics, Inc. does not currently pay a dividend.
Profit growth
LossElicio Therapeutics, Inc. made a loss in each of the last two years.
Interest cover
Not coveredElicio Therapeutics, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashElicio Therapeutics, Inc. held $4 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Elicio Therapeutics, Inc.: $53 M ÷ $8 M (30 Jun 2026) = 6.6.
What is Elicio Therapeutics, Inc.'s return on equity?
Elicio Therapeutics, Inc. lost 774.6% of its shareholders' money over the last year, lower than 96% of Healthcare companies in United States.
How much does Elicio Therapeutics, Inc. owe compared with what it owns?
Elicio Therapeutics, Inc. owes $0.75 for every $1 it owns (moderate), higher than 75% of Healthcare companies in United States.
Does Elicio Therapeutics, Inc. pay a dividend?
No. Elicio Therapeutics, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.